Rewrite this content
Posted Jan 30, 2023, 7:32 AM
PARIS (Agefi-Dow Jones)–The pharmaceutical company Sanofi announced on Monday that the European Commission (EC) has extended the marketing authorization for its drug Dupixent in the European Union (EU) for the treatment of eosinophilic esophagitis in adults and adolescents.
“With this approval, Dupixent is the first and only targeted drug indicated expressly for the treatment of eosinophilic esophagitis in Europe and the United States,” Sanofi said in a statement.
“Dupixent, the trade name for dupilumab, is now a treatment option for approximately 50,000 adults and adolescents with severe uncontrolled eosinophilic esophagitis in the European Union (EU),” added Sanofi.
Eosinophilic esophagitis is a chronic inflammatory disease of the esophagus, which causes difficulty swallowing.
Dupixent is now approved in the EU for the treatment of five diseases with type 2 inflammatory signature.
Sanofi and its partner, the American company Regeneron, are devoting several additional phase 3 trials to Dupixent, which has already been approved in several countries for the treatment of atopic dermatitis, asthma and nasal polyposis.
-Pierre-Jean Lepagnot, Agefi-Dow Jones +33(0)141274795; [email protected] ed: DID
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
January 30, 2023 01:32 AM ET (06:32 GMT)
and and more content about Sanofi: the EC authorizes Dupixent against eosinophilic esophagitis in adults
